- Thermo Fisher Scientific2010年2月22日 13:11 点击：2225
2010年2月22日，中国上海 —— BUSINESS WIRE 近日报道，全球科学服务领域的领导者赛默飞世尔科技（纽约证交所代码：TMO）于2010年2月1日宣布，已经正式签署了收购Finnzymes的协议。Finnzymes是知名的分子生物学分析工具供应商，产品包括试剂、仪器、耗材和试剂盒。Finnzymes的总部在芬兰的Espoo，拥有90名员工，2009年的销售额是2千万美元。
赛默飞世尔科技通过对Finnzymes的收购，增加了DNA聚合酶、PhireTM和PhusionTM、迷你PCR仪、新型PCR管和PCR板等产品，扩大了用于分子生物学研究和诊断试剂市场的试剂和耗材产品线。这些新增产品很好地补充了赛默飞世尔最近发布Thermo Scientific Solaris qPCR基因表达分析产品，并与后者一起为客户提供完整的解决方案。来自于Thermo Scientific的基于MGB®的基因特异性探针和来自于Finnzymes先进的酶技术结合在一起，将进一步提高qPCR分析技术。
“Finnzymes创新的酶产品和独特的PCR仪器平台的加盟进一步扩大了我们的生命科学试剂与耗材的产品覆盖范围，提高了我们的专业诊断产品的供应能力。”赛默飞世尔科技的首席执行官Marc N. Casper说：“这次合并使分子生物学和诊断学的一些关键技术也整合到了一起，让我们有能力为我们的客户创造更高的价值。”
关于赛默飞世尔科技（Thermo Fisher Scientific）
赛默飞世尔科技有限公司（Thermo Fisher Scientific Inc.）（纽约证交所代码：TMO）是全球科学服务领域的领导者，致力于帮助客户使世界变得更健康、更清洁、更安全。公司年度营收达到105亿美元，拥有员工35,000多人，为350,000多家客户提供服务。这些客户包括：医药和生物技术公司、医院和临床诊断实验室、大学、研究院和政府机构以及环境与工业过程控制装备制造商等。该公司借助于 Thermo Scientific 和 Fisher Scientific 这两个主要品牌，帮助客户解决从常规测试到复杂的研发项目中所面临的各种分析方面的挑战。Thermo Scientific 能够为客户提供一整套包括高端分析仪器、实验室装备、软件、服务、耗材和试剂在内的实验室工作流程综合解决方案。Fisher Scientific 则提供了一系列用于卫生保健，科学研究，以及安全和教育领域的实验室装备、化学药品以及其他用品和服务。赛默飞世尔科技将努力为客户提供最为便捷的采购方案，为科研的飞速发展不断地改进工艺技术，并提升客户价值，帮助股东提高收益，为员工创造良好的发展空间。欲获取更多信息，请登陆：www.thermofisher.com（英文），www.thermo.com.cn（中文）。
Thermo Fisher Scientific新闻稿
Thermo Fisher Scientific Signs Agreement to Acquire High-Performance PCR Solution Provider, Finnzymes
WALTHAM, Mass., Feb 01, 2010 (BUSINESS WIRE) -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has signed a definitive agreement to acquire Finnzymes, a well-recognized provider of integrated tools for molecular biology analysis, including reagents, instruments, consumables and kits. Headquartered in Espoo, Finland, Finnzymes has 90 employees and generated revenue of $20 million in 2009.
Finnzymes provides comprehensive solutions for high-performance polymerase chain reaction (PCR), reverse transcription-PCR (RT-PCR) and real-time quantitative PCR (qPCR). The company's expertise in DNA polymerases has led to significant increases in the performance of these enzymes, making the PCR process faster and more accurate. The ability to quickly and reproducibly amplify and quantify particular DNA sequences benefits a variety of applications, including basic genomic research, genetic testing, forensics and food testing.
The acquisition of Finnzymes expands Thermo Fisher's portfolio of reagents and other consumables for the molecular biology research and diagnostics markets through the addition of its proprietary DNA polymerases, Phire(TM) and Phusion(TM), and high-speed miniaturized thermal cyclers and innovative plastic tubes and plates. These products complement the recently launched Thermo Scientific Solaris qPCR gene expression assays and, together, deliver a more complete solution for customers. Combining the gene-specific MGB(R)-based probes from Thermo Scientific with the advanced enzyme performance from Finnzymes will further enhance qPCR assay technology.
"The addition of Finnzymes' innovative enzyme portfolio and unique PCR instrument platform strengthens our broad range of life science reagents and consumables, as well as our specialty diagnostics product offering," said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. "This combination brings together key complementary technologies for molecular biology and diagnostics, allowing us to create significant value for our customers."
Finnzymes will be integrated primarily into Thermo Fisher Scientific's Analytical Technologies Segment, with some equipment and consumables product lines being added to the Laboratory Products and Services Segment. The transaction is expected to close during the first quarter of 2010. The company does not expect this transaction to have a material impact on its 2010 financial results.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With 2008 revenues of $10.5 billion, we have approximately 35,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit //www.thermofisher.com.
The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company's Quarterly Report on Form 10-Q for the period ended September 26, 2009, under the caption "Risk Factors," which is on file with the Securities and Exchange Commission and available in the "Investors" section of our Website under the heading "SEC Filings." Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; general worldwide economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; the effect of laws and regulations governing government contracts; the effect of competing with certain of our customers and suppliers; and the effect of rapid changes in the healthcare industry. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
SOURCE: Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
Media Contact Information:
Ron O'Brien, 781-622-1242
Investor Contact Information:
Ken Apicerno, 781-622-1294
- 凡本网注明“来源：来宝网”的所有作品，版权均属于来宝网，转载请必须注明来宝网， 时时彩网络平台，违反者本网将追究相关法律责任。